KR20190138683A - 망막병증을 치료하기 위한 조성물 및 방법 - Google Patents

망막병증을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190138683A
KR20190138683A KR1020197033914A KR20197033914A KR20190138683A KR 20190138683 A KR20190138683 A KR 20190138683A KR 1020197033914 A KR1020197033914 A KR 1020197033914A KR 20197033914 A KR20197033914 A KR 20197033914A KR 20190138683 A KR20190138683 A KR 20190138683A
Authority
KR
South Korea
Prior art keywords
tyrosine
methyl
amino
propanoate
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197033914A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 호프만
Original Assignee
스티븐 호프만
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 호프만 filed Critical 스티븐 호프만
Publication of KR20190138683A publication Critical patent/KR20190138683A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020197033914A 2017-04-21 2018-04-20 망막병증을 치료하기 위한 조성물 및 방법 Withdrawn KR20190138683A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488161P 2017-04-21 2017-04-21
US62/488,161 2017-04-21
PCT/US2018/028552 WO2018195411A1 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Publications (1)

Publication Number Publication Date
KR20190138683A true KR20190138683A (ko) 2019-12-13

Family

ID=62117055

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033914A Withdrawn KR20190138683A (ko) 2017-04-21 2018-04-20 망막병증을 치료하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (2) US11351136B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612225A1 (cg-RX-API-DMAC7.html)
JP (1) JP7171611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190138683A (cg-RX-API-DMAC7.html)
CN (1) CN110769855A (cg-RX-API-DMAC7.html)
AU (1) AU2018254556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3060417A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992515A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012476A (cg-RX-API-DMAC7.html)
PH (1) PH12019502380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018195411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451422A1 (en) * 1990-04-13 1991-10-16 Merrell Dow Pharmaceuticals Inc. Pharmaceutically active fluoromethyltyrosine compounds
MXPA02002559A (es) * 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
JP4758581B2 (ja) 1999-11-30 2011-08-31 アルコン,インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
EP2114386B9 (en) 2007-01-29 2013-09-18 Vlife Sciences Technologies Pvt Ltd. Pharmaceutical composition for treatment of diabetic complications
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JP6836991B2 (ja) 2014-12-23 2021-03-03 スティーブン・ホフマン 経皮製剤
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Also Published As

Publication number Publication date
US20180303783A1 (en) 2018-10-25
US11351136B2 (en) 2022-06-07
AU2018254556A1 (en) 2019-11-14
JP7171611B2 (ja) 2022-11-15
MX2019012476A (es) 2020-02-12
CN110769855A (zh) 2020-02-07
US20220288003A1 (en) 2022-09-15
PH12019502380A1 (en) 2020-09-14
EP3612225A1 (en) 2020-02-26
US12364676B2 (en) 2025-07-22
CA3060417A1 (en) 2018-10-25
JP2020517663A (ja) 2020-06-18
AU2018254556B2 (en) 2024-05-02
EA201992515A1 (ru) 2020-04-09
WO2018195411A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
JP7737367B2 (ja) α1A-AR部分アゴニストを用いて神経障害を治療するための方法
JP2019203003A (ja) 腸透過性亢進を治療するための組成物及び方法
US12364676B2 (en) Compositions and methods for treating retinopathy
EA038339B1 (ru) Способы лечения аутизма
JPWO2020129964A1 (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
US20230052152A1 (en) Compounds for treatment of alzheimer's disease
AU2017232348A1 (en) Pharmaceutical compositions for the treatment of cancer
US20170151242A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
JP2018172400A (ja) フェノキシプロピルアミン化合物を使用してうつ病を治療する方法
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
EA046053B1 (ru) Композиции и способы для лечения ретинопатии
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
AU2013270622B2 (en) Composition and method for treating or preventing skeletal muscle fibrosis
OA21243A (en) Compounds for treatment of alzheimer's disease.
AU2018202423A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination